Cargando…

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

BACKGROUND: The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of this pathway would enhance urinary glucose excretion (UGE)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussey, Elizabeth K, Kapur, Anita, O’Connor-Semmes, Robin, Tao, Wenli, Rafferty, Bryan, Polli, Joseph W, James, Charles D, Dobbins, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682882/ https://www.ncbi.nlm.nih.gov/pubmed/23631443 http://dx.doi.org/10.1186/2050-6511-14-25

Ejemplares similares

Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin
por: Dobbins, Robert, et al.
Publicado: (2021)

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
por: Kapur, Anita, et al.
Publicado: (2013)

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
por: Mudaliar, Sunder, et al.
Publicado: (2012)

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
por: Napolitano, Antonella, et al.
Publicado: (2013)

Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
por: Mohan, Viswanathan, et al.
Publicado: (2020)

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
por: Jain, Rajesh, et al.
Publicado: (2022)

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
por: Dharmalingam, Mala, et al.
Publicado: (2020)

The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)

Development and Validation of Green UV Derivative Spectrophotometric Methods for Simultaneous Determination Metformin and Remogliflozin from Formulation: Evaluation of Greenness
por: Attimarad, Mahesh, et al.
Publicado: (2021)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses
por: Agne, Gustavo F., et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection
por: Engwerda, Elsemiek E. C., et al.
Publicado: (2017)

Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats
por: Roche‐Catholy, Marine, et al.
Publicado: (2022)

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy
por: Le, KN, et al.
Publicado: (2015)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%
por: Cavet, Megan E., et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus
por: Sun, Lin, et al.
Publicado: (2011)

Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits
por: Nagaraju, Beere, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
por: Chang, Hsuan-Ping, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of intranasal and intramuscular administration of naloxone in working dogs administered fentanyl
por: Barr, Ciara A., et al.
Publicado: (2023)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of (S)-Ketoprofen Co-Administered with Caffeine: A Preclinical Study in Arthritic Rats
por: Medina-López, Raúl, et al.
Publicado: (2018)

A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis
por: Zuo, P, et al.
Publicado: (2016)

Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
por: Taylor, Simeon I., et al.
Publicado: (2023)

Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation
por: Attimarad, Mahesh, et al.
Publicado: (2021)

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard, John D, et al.
Publicado: (2014)

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
por: Sheppard, John D., et al.
Publicado: (2016)

Assessment of Pharmacodynamic and Pharmacokinetic Interaction of Aqueous Extract of Cassia auriculata L. and Metformin in Rats
por: Elango, Hemnath, et al.
Publicado: (2015)

SUN-LB112 Efficacy & Safety After Switchover to Remogliflozin in Indian T2DM Patients - a Real World Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose‐escalating trial
por: Buchtele, Nina, et al.
Publicado: (2020)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults
por: Choi, Suein, et al.
Publicado: (2018)

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Erratum: Population Pharmacokinetic Analysis of Metformin Administered as Fixed-Dose Combination in Korean Healthy Adults
por: Choi, Suein, et al.
Publicado: (2018)

Development and Greenness Assessment of HPLC Method for Studying the Pharmacokinetics of Co-Administered Metformin and Papaya Extract
por: Abdelgawad, Mohamed A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n9mbgkima8j4ntb92iu0huvkr9